ImGTS for Patients With Behavioral and Psychological Symptoms of Dementia (Phase 2)
Study Details
Study Description
Brief Summary
The proposed research project aims to answer the question "Are immersive technology systems effective in the management and treatment of patients with BPSD?". This project is composed of three phases and the current study is the second phase. The phase 2 trial aims to create an immersive technology system for managing the behavioral and psychological symptoms of dementia and determine its clinical effectiveness, safety, usability, and acceptability among patients with mild to moderate Alzheimer's disease.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Head-mounted display (HMD) The HMD system uses a commercially available virtual headset, the Oculus/Meta Quest 2, which allows a user to view a virtual environment in 360 degrees and to interact with the environment using hand-tracking technology (i.e., when a user's hand is projected into the virtual world to be used for interactions and gestures). |
Other: Virtual reality
A role-playing game with activities based on existing therapy activities (such as orientation therapy, reminiscence therapy, art therapy, and music therapy) that are used to manage behavioral and psychological symptoms of dementia
|
| Experimental: Semi-cave automatic virtual environment (semi-CAVE) The semi-CAVE system uses projectors and projector screens to provide a 270-degree view of the virtual environment. These projectors are connected to a powerful workstation (desktop computer), which uses HTC Vive trackers and base stations to track user movements and interactions |
Other: Virtual reality
A role-playing game with activities based on existing therapy activities (such as orientation therapy, reminiscence therapy, art therapy, and music therapy) that are used to manage behavioral and psychological symptoms of dementia
|
Outcome Measures
Primary Outcome Measures
- Incidence of behavioral and psychological symptoms of dementia will be assessed using the Neuropsychiatric Inventory-12 [Within one hour after completion of the fourth session]
The NPI evaluates the degree and severity of BPSDs and the distress it causes the primary caregiver. Scores range from 0 to 120 where higher scores indicate greater psychiatric disturbance.
- Incidence of virtual reality sickness symptoms will be assessed using the Virtual Reality Sickness Questionnaire [Immediately after each intervention, within an hour of completion of the virtual reality game]
The VRSQ will measure a participant's experience with the following symptoms: general discomfort, fatigue, eye strain, difficulty focusing, headache, fullness of head, blurring of vision, dizziness (when eyes are closed), and vertigo. Symptoms will be rated on a 4-point scale: 0 or None, 1 or Slight, 2 or Moderate, and 3 or Severe.
- Usability of the virtual reality intervention will be assessed using the System Usability Scale [Immediately after each intervention, within an hour of completion of the virtual reality game]
The SUS is a 10-item questionnaire that is widely used in the evaluation of various kinds and aspects of technology. Each question has five response options ranging from 'Strongly agree' to 'Strongly disagree', which has a corresponding number value. Each response is added and multiplied by 2.5 to obtain the final score that ranges from 0 to 100. A SUS score above 68 is considered above average.
Secondary Outcome Measures
- Cognitive function will be assessed using MOCA-P [Within one hour after completion of the fourth session]
Montreal Cognitive Assessment-Philippines (MOCA-P) is a 30-item test that takes about 10-12 minutes to complete. The test measures different cognitive domains such as visuospatial/executive, naming, memory, attention, language, abstraction, and orientation.
- Cognitive function will be assessed using MMSE [Within one hour after completion of the fourth session]
The Mini-Mental State Exam (MMSE) is a 30-item test for cognitive function. It assesses attention, orientation, memory, registration, recall, calculation, language, and an individual's ability to draw a complex polygon.
- Cognitive function will be assessed using ADAS-Cog [Within one hour after completion of the fourth session]
The cognitive subscale of the Alzheimer's Disease Assessment Scale (ADAS-Cog) is an 11-item tool for the assessment of the following tasks: word recall, naming objects and fingers, commands, constructional praxis, ideational praxis, orientation, word recognition, and language.
- Activities of daily living will be assessed using ADCS-ADL [Within one hour after completion of the fourth session]
The Alzheimer's Disease Cooperative Study - Activities of Daily Living Inventory (ADCS-ADL) is a 24-item assessment on activities of daily living within the past four weeks
- Health-related quality of life will be assessed using DEMQOL [Within one hour after completion of the fourth session]
The Health-related quality of life for people with dementia (DEMQOL) is a 28-item self-report measure of quality of life specific for persons with mild-to-moderate dementia. It covers four dimensions of quality of life, namely, daily activities, memory, negative emotion, and positive emotion.
Other Outcome Measures
- Acceptability [Within one day after completing virtual reality experience]
Acceptability will be measured among a small group of patients and their caregivers through an interview and a focus group discussion
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Aged 60 years old or older
-
Diagnosed with mild to moderate Alzheimer's dementia according to the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria
-
Montreal Cognitive Assessment-Philippines (MOCA-P) score of 10-20 inclusive
-
Neuropsychiatric Inventory (NPI-12) score 1-50 inclusive
-
Reisberg Scale Stage 4-5 inclusive
-
Stable dose of antidepressants for the past 6 weeks
-
Stable dose of antipsychotics for the past 4 weeks
-
Able to walk unassisted or with minimal assistance, with or without assistive device
-
No other explanation for condition based on reasonable clinical diagnostics
Exclusion Criteria:
-
Have mild cognitive impairment (no dementia)
-
Have MOCA-P score less than 10 or more than 20
-
Other non-amnestic dementia syndromes
-
Have receptive aphasia
-
Have significant visual or hearing impairment
-
Have an active psychiatric disorder prior to Alzheimer dementia diagnosis
-
Had previous episodes of seizures, diagnosis of epilepsy, or intake of antiepileptic or seizure medications
-
Have quadriplegia or paralysis of the dominant hand
-
Have a history of motion sickness
-
Experience claustrophobia
-
Have a diagnosis of a terminal illness or a life expectancy of less than one year
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | University of the Philippines College of Allied Medical Professions Immersive Technology Laboratory | City Of Manila | National Capital Region | Philippines | 1000 |
Sponsors and Collaborators
- Augmented eXperience E-health Laboratory
Investigators
- Principal Investigator: Veeda Michelle M. Anlacan, MD, University of the Philippines Manila
Study Documents (Full-Text)
None provided.More Information
Publications
- AXEL0003